Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:TFX
CUSIP87936910
Phone610-225-6800
Debt
Debt-to-Equity Ratio0.84
Current Ratio2.18
Quick Ratio1.45
Price-To-Earnings
Trailing P/E Ratio32.82
Forward P/E Ratio28.10
P/E Growth1.93
Sales & Book Value
Annual Sales$2.15 billion
Price / Sales5.85
Cash Flow$12.2036 per share
Price / Cash22.59
Book Value$53.95 per share
Price / Book5.11
Profitability
EPS (Most Recent Fiscal Year)$8.40
Net Income$152.53 million
Net Margins7.51%
Return on Equity16.60%
Return on Assets6.95%
Miscellaneous
Employees14,400
Outstanding Shares45,540,000
Market Cap$12,555.57
Teleflex (NYSE:TFX) Frequently Asked Questions
What is Teleflex's stock symbol?
Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."
How often does Teleflex pay dividends? What is the dividend yield for Teleflex?
Teleflex announced a quarterly dividend on Monday, May 7th. Investors of record on Tuesday, May 15th will be paid a dividend of $0.34 per share on Friday, June 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Monday, May 14th. View Teleflex's Dividend History.
How were Teleflex's earnings last quarter?
Teleflex Incorporated (NYSE:TFX) released its quarterly earnings results on Thursday, May, 3rd. The medical technology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.94 by $0.21. The medical technology company had revenue of $587.23 million for the quarter, compared to analyst estimates of $568.29 million. Teleflex had a return on equity of 16.60% and a net margin of 7.51%. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.80 EPS. View Teleflex's Earnings History.
When is Teleflex's next earnings date?
What price target have analysts set for TFX?
10 analysts have issued twelve-month target prices for Teleflex's stock. Their predictions range from $253.00 to $317.00. On average, they expect Teleflex's stock price to reach $284.4444 in the next twelve months. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Ratings for Teleflex.
What is the consensus analysts' recommendation for Teleflex?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Teleflex stock?
Here are some recent quotes from research analysts about Teleflex stock:
- 1. Needham & Company LLC analysts commented, "TFX is hosting an analyst day on 5/11/18 in New York. We note that TFX is on track to beat three out of four of its long range plan (LRP) targets (revenue growth, gross margin improvement, operating margin improvement, and free cash flow growth) from its 2015 analyst day. Assuming that TFX updates its prior four targets for 2019-2021, we expect it to target organic revenue growth that is slightly below consensus (~50 bps) and to set targets in line with consensus for the other items. We expect investors to view the revenue growth target at conservative, however, and don’t expect a negative stock reaction. We have also provided a list of ten questions that we think will be important for management to address at the analyst day (see page 2). We expect the analyst day to be a positive catalyst and reiterate our Buy rating." (5/9/2018)
- 2. According to Zacks Investment Research, "Teleflex Inc. designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company offers its products to hospitals and healthcare providers through its direct sales force and distributors. Teleflex was founded in 1943 and is headquartered in Wayne, Pennsylvania. " (10/4/2017)
- 3. Barclays PLC analysts commented, "XLRS Progressing Slowly with Some Uncertainty. Although top-line safety data from 12 patients in the Phase I/II XLRS dose escalation study did not reveal SAEs and moderate ocular inflammation was considered manageable, the combination of inter-patient and test variability has affected the ability to determine a therapeutic effect. As a result, AGTC plans to expand enrollment and follow the new patients for at least six months." (9/12/2017)
Who are some of Teleflex's key competitors?
Some companies that are related to Teleflex include Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR) and Merit Medical Systems (MMSI).
Who are Teleflex's key executives?
Teleflex's management team includes the folowing people:
- Mr. Liam J. Kelly, Pres & CEO (Age 51)
- Mr. Thomas E. Powell, Exec. VP & CFO (Age 56)
- Mr. Thomas Anthony Kennedy, Sr. VP of Global Operations (Age 55)
- Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 51)
- Mr. John R. Deren, VP & Chief Accounting Officer
Has Teleflex been receiving favorable news coverage?
Media coverage about TFX stock has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Teleflex earned a coverage optimism score of 0.07 on Accern's scale. They also gave press coverage about the medical technology company an impact score of 47.53 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Teleflex's major shareholders?
Teleflex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.10%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.04%), Gulf International Bank UK Ltd (0.03%), NN Investment Partners Holdings N.V. (0.02%), State of Alaska Department of Revenue (0.01%) and Pennsylvania Trust Co (0.01%). Company insiders that own Teleflex stock include Benson Smith, Cameron P Hicks, George Babich Jr, Gretchen R Haggerty, Jeffrey A Graves, John Deren, Stephen K MD Klasko, Stuart A Randle and Thomas E Powell. View Institutional Ownership Trends for Teleflex.
Which institutional investors are selling Teleflex stock?
TFX stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC, Fisher Asset Management LLC, First Citizens Bank & Trust Co. and Legacy Private Trust Co.. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, George Babich Jr, John Deren, Stephen K MD Klasko and Thomas E Powell. View Insider Buying and Selling for Teleflex.
Which institutional investors are buying Teleflex stock?
TFX stock was bought by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, NN Investment Partners Holdings N.V., Clinton Group Inc., State of Alaska Department of Revenue, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd and Pennsylvania Trust Co. View Insider Buying and Selling for Teleflex.
How do I buy shares of Teleflex?
Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teleflex's stock price today?
One share of TFX stock can currently be purchased for approximately $275.68.
How big of a company is Teleflex?
Teleflex has a market capitalization of $12.56 billion and generates $2.15 billion in revenue each year. The medical technology company earns $152.53 million in net income (profit) each year or $8.40 on an earnings per share basis. Teleflex employs 14,400 workers across the globe.
How can I contact Teleflex?
Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]
MarketBeat Community Rating for Teleflex (NYSE TFX)
MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
